Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Inflammation Research
Erschienen in: Inflammation Research 4/2013

01.04.2013 | Original Research Paper

Hesperidin alleviates oxidative stress and downregulates the expressions of proliferative and inflammatory markers in azoxymethane-induced experimental colon carcinogenesis in mice

verfasst von: Gowrikumar Saiprasad, Palanivel Chitra, Ramar Manikandan, Ganapasam Sudhandiran

Erschienen in: Inflammation Research | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

Colon cancer is a common malignant neoplasm causing huge morbidity and mortality worldwide. Current therapeutic interventions are unsatisfying, which necessitates novel chemopreventive strategies. The present study was intended to elucidate the chemopreventive efficacy of hesperidin against azoxymethane (AOM)-induced mouse colon carcinogenesis.

Materials and methods

Swiss albino mice were subjected to intraperitoneal injections of AOM once a week for 3 consecutive weeks. Hesperidin treatments were provided in the initiation or post-initiation phases. The number and multiplicity of aberrant crypt foci (ACF), tumor incidence and antioxidant status were determined. Histopathological analyses, proliferating cell nuclear antigen (PCNA) index and modulations in the expression of inflammatory markers such as nuclear factor kappa B (NF-κB), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were studied.

Results

Hesperidin treatments significantly inhibited the number and multiplicities of AOM-induced ACF and tumor incidence. Hesperidin reduced oxidative stress parameters and enhanced antioxidant status. A marked decrease in the PCNA index was evident on hesperidin administration. Hesperidin treatments caused a prominent downregulation of NF-κB and its target molecules iNOS and COX-2, thereby combating inflammation.

Conclusion

This study proves the chemopreventive efficacy of hesperidin against the deleterious traits of colon carcinogenesis including accelerated proliferation, inflammation and persistent oxidative stress.
Literatur
1.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics 2011: the impact of eliminating socio economic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRef
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Thompson PA, Gerner EW. Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol. 2009;3:369–82.PubMedCrossRef
4.
Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, Colditz GA. Comparison of risk factors for colon and rectal cancer. Int J Cancer. 2004;108:433–42.PubMedCrossRef
5.
Tapas AR, Sakarkar DM, Kakde RB. Flavonoids as nutraceuticals: a review. Trop J Pharm Res. 2008;7:1089–99.CrossRef
6.
Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther. 2001;90:157–77.PubMedCrossRef
7.
Boateng J, Verghese M, Shackelford L, Walker LT, Khatiwada J, Ogutu S, Williams DS, Jones J, Guyton M, Asiamah D, Henderson F, Grant L, DeBruce M, Johnson A, Washington S, Chawan CB. Selected fruits reduce azoxymethane (AOM)-induced aberrant crypt foci (ACF) in Fisher 344 male rats. Food Chem Toxicol. 2007;45:725–32.PubMedCrossRef
8.
Nishino H, Tokuda H, Satomi Y, Masuda M, Onozuka M, Yamaguchi S, Takayasu J, Tsuruta J, Takemura M, Ii T, Ichiishi E, Kuchide S, Okuda M, Murakoshi M. Cancer chemoprevention by phytochemicals and their related compounds. Asian Pac J Cancer Prev. 2000;1:49–55.PubMed
9.
Benavente OG, Castillo J, Alcaraz M, Vicente V, Del JA, Ortuno A. Beneficial action of Citrus flavonoids on multiple cancer-related biological pathways. Curr Cancer Drug Targets. 2007;7:795–809.CrossRef
10.
Garg A, Garg S, Zaneveld LJ, Singla AK. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother Res. 2001;15:655–69.PubMedCrossRef
11.
Patricia KW, Dalla SS, Mirian S. Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. J Agric Food Chem. 2005;53:4757–61.CrossRef
12.
Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S, Devaki T. Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice. Invest New Drugs. 2009;27:214–22.PubMedCrossRef
13.
Leef KH, Yehb MH, Kao ST, Hung CM, Liu CJ, Huang YY, Yeh CC. The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-kappa B in human hepatocellular carcinoma cells. Toxicol Lett. 2010;194:42–9.CrossRef
14.
Andriantsitohaina R, Duluc L, Rodriguez JCG, Valle LGD, Garcia MG, Simard G, Soleti R, Su DF, Perez LV, Wilson JX, Laher I. Systems biology of antioxidants. Clin Sci (Lond). 2012;123:173–92.CrossRef
15.
Heijstek MW, Kranenburg O, Rinkes IHMB. Mouse models of colorectal cancer and liver metastases. Dig Surg. 2005;22:16–25.PubMedCrossRef
16.
Ashokkumar P, Sudhandiran G. Protective role of luteolin on the status of lipid peroxidation and antioxidant defence against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother. 2008;62:590–7.PubMedCrossRef
17.
Beelen VA, Spenkelink B, Mooibroek H, Sijtsma L, Bosch D, Rietjens IM, Alink GM. An n-3 PUFA-rich microalgal oil diet protects to a similar extent as a fish oil-rich diet against AOM-induced colonic aberrant crypt foci in F344 rats. Food Chem Toxicol. 2009;47:316–20.PubMedCrossRef
18.
Wargovich MJ, Brown VR, Morris J. Aberrant crypt foci: the case for inclusion as a biomarker for colon cancer. Cancers. 2010;2:1705–16.CrossRef
19.
Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990;162:285–94.PubMedCrossRef
20.
Pikarsky E, Neriah YB. NF-κB inhibition: a double-edged sword in cancer? Eur J Cancer. 2006;42:779–84.PubMedCrossRef
21.
Murakami A, Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer. 2007;21:2357–63.CrossRef
22.
Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumor progression. Lancet Oncol. 2001;2:149–56.PubMedCrossRef
23.
Watanabe K, Kawamori T, Nakatsugi S, Wakabayashi K. COX-2 and iNOS, good targets for chemoprevention of colon cancer. BioFactors. 2000;12:129–33.PubMedCrossRef
24.
Bird RP. Observation and quantification of aberrant crypt foci in murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 1987;37:147–51.PubMedCrossRef
25.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.PubMed
26.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1972;95:351–8.CrossRef
27.
Cederbaum AI, Cohen G. In: Packer L, editor, Methods in enzymology. San Diego: Academic Press; 1984. pp. 516–522.
28.
Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247:3170–5.PubMed
29.
30.
Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179:588–90.PubMedCrossRef
31.
Staal GE, Visser J, Veeger C. Purification and properties of glutathione reductase of human erythrocytes. Biochim Biophys Acta. 1969;185:39–48.PubMedCrossRef
32.
Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;4:67–78.CrossRef
33.
Omaye ST, Urnbull JB, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues and fluids. Methods Enzymol. 1979;62:1–11.
34.
35.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 1998;339:1277–84.PubMedCrossRef
36.
Miyamoto S, Yasui Y, Ohigashi H, Tanaka T, Murakami A. Dietary flavonoids suppress azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Chem Biol Interact. 2010;18:276–83.CrossRef
37.
Gee JM, Hara H, Johnson IT. Suppression of intestinal crypt cell proliferation and aberrant crypt foci by dietary quercetin in rats. Nutr Cancer. 2002;43:193–201.PubMedCrossRef
38.
Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male f344 rats. Int J Cancer. 2002;101:461–8.PubMedCrossRef
39.
Leonardi T, Vanamala J, Taddeo SS, Davidson LA, Murphy ME, Patil BS, Wang N, Carroll RJ, Chapkin RS, Lupton JR, Turner ND. Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp Biol Med. 2010;23:710–7.
40.
Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.PubMedCrossRef
41.
Skrzydlewska E, Stankiewicz A, Sulkowska M, Sulkowski S, Kasacka I. Antioxidant status and lipid peroxidation in colorectal cancer. J Toxicol Environ Health. 2001;64:213–22.CrossRef
42.
Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2000;160:1–40.CrossRef
43.
Mates JM, Sanchez JF. Antioxidant enzymes and the implications in pathophysiologic processes. Front Biosci. 1999;4:D339–45.PubMedCrossRef
44.
Roberta M, Roberta DB, Rosaria V, Carmela F, Claudio G. Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes. J Nutr Biochem. 2005;16:577–86.CrossRef
45.
Kojo S. Vitamin C: basic metabolism and its function as an index of oxidative stress. Curr Med Chem. 2004;11:1041–64.PubMedCrossRef
46.
Burton GW, Ingold KU. Auto oxidation of biological molecules: the antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. J Am Chem Soc. 1981;103:64–72.
47.
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.PubMedCrossRef
48.
Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995;55:1811–6.PubMed
49.
Galati G, Teng S, Moridani MY, Chan TS, Brien PJO. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol Drug Interact. 2000;17:311–49.PubMedCrossRef
50.
Kubben FJGM, Haesevoets AP, Engels LGJB, Baeten CGMI, Schutte B, Arends JW, Stockbrugger RW, Blijham GH. Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation. Gut. 1994;35:530–5.PubMedCrossRef
51.
Ravichandran K, Velmurugan B, Gu M, Singh RP, Agarwal R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res. 2010;16:4595–606.PubMedCrossRef
52.
Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary-feeding of grape seed extract prevents azoxymethane-induced colonic aberrant crypt foci formation in Fischer 344 rats. Mol Carcinog. 2010;49:641–52.PubMed
53.
Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–14.PubMedCrossRef
54.
Perkins ND. Integrating cell-signalling pathways with NF-kappa B and IKK function. Nat Rev Mol Cell Biol. 2007;8:49–62.PubMedCrossRef
55.
Karin M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1:a000141.PubMedCrossRef
56.
Wang S, Liu Z, Wang L, Zhang X. NF-kB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6:327–34.PubMedCrossRef
57.
Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M, Katano M. Increased nuclear factor-κB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004;24:675–82.PubMed
58.
Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res. 2004;555:107–19.PubMedCrossRef
59.
Williams CS, Mann M, Dubois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–16.PubMedCrossRef
Metadaten
Titel
Hesperidin alleviates oxidative stress and downregulates the expressions of proliferative and inflammatory markers in azoxymethane-induced experimental colon carcinogenesis in mice
verfasst von
Gowrikumar Saiprasad
Palanivel Chitra
Ramar Manikandan
Ganapasam Sudhandiran
Publikationsdatum
01.04.2013
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 4/2013
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-013-0595-2

Weitere Artikel der Ausgabe 4/2013

Inflammation Research 4/2013 Zur Ausgabe

Original Research Paper

Anti-inflammatory effect of quinoline alkaloid skimmianine isolated from Ruta graveolens L.

Original Research Paper

Identification of macrophage genes responsive to extracellular acidification

Original Research Paper

Endothelin-3 at low concentrations attenuates inflammatory responses via the endothelin B2 receptor

Original Research Paper

Lipopolysaccharide-induced failure of the gut barrier is site-specific and inhibitable by growth hormone

Original Research Paper

Overexpression of histamine H4 receptors in the kidney of diabetic rat

Original Research Paper

SHPS-1 and a synthetic peptide representing its ITIM inhibit the MyD88, but not TRIF, pathway of TLR signaling through activation of SHP and PI3K in THP-1 cells

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise